Protocol
13-002
Full Title
The Feasibility of Paclitaxel with Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Purpose
Paclitaxel and trastuzumab are drugs used in the standard treatment of early-stage breast cancers that overproduce a protein called HER2 (the target of trastuzumab). Despite this treatment, however, some women experience a recurrence of their cancer. Lapatinib is a newer drug that targets HER2 in a way different than trastuzumab; it is approved for the treatment of advanced breast cancer when given in combination with certain other drugs.
The purpose of this study is to see if it is feasible to give paclitaxel, trastuzumab, and lapatinib together in women with early-stage HER2-positive breast cancer. Researchers are conducting this study to observe the side effects of this drug combination in these patients.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have early-stage breast cancer (a tumor size of 3 cm or less and no spread to the lymph nodes) that is positive for HER2.
- Patients should begin receiving the study treatment within 90 days of completing breast cancer surgery.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Chau Dang at 646-888-5426.
Disease(s)
Breast Cancer
Locations
ClinicalTrials.gov
Related Diseases
